This article was originally published on Urbanhealth Today Across the globe, socioeconomic status (SES) was shown to be a prognosis factor for...
Myeloma NZ
Colorectal Cancer in a Patient With Multiple Myeloma: A Treatment Dilemma
This article was originally published on Urbanhealth Today ABSTRACT Multiple myeloma (MM) is a malignancy of plasma cells characterized by the...
Large Meta-Analysis Confirms Predictive Value of MRD Negativity in Myeloma
Achievement of measurable residual disease (MRD) negativity is associated with significant improvements in progression-free survival (PFS) and...
Smoldering multiple myeloma 40 years later: a story of unintended disease
This article was originally posted on DocwireNews ABSTRACT INTRODUCTION: : Smoldering multiple myeloma (SMM) is a clonal plasma cell (PC) disorder...
Higher Rates of COVID-19 Mortality for Patients with Multiple Myeloma
This article was originally posted on Docwirenews According to new data published in Blood, patients with multiple myeloma (MM) who...
Saad Z. Usmani, MD, MBA, FACP, on the Latest in Multiple Myeloma Research
This article was originally published on Cancer Network Treatment options for multiple myeloma only continued to improve over the course of 2020,...
Insurance Status Linked to Survival for Patients with Multiple Myeloma
This article was originally published on UrbanhealthToday Insurance status was found to be significantly associated with survival for patients with...
A Beginner’s Guide to Understanding Myeloma
This article was originally published on Curetoday The last 15 years have proved pivotal for patients with myeloma, as the Food and Drug...
Understanding New Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma
This article was originally published Cure There has been tremendous growth over the years in terms of treatment options for patients with multiple...
Subcut daratumumab: reducing treatment burden in myeloma
This article was originally published on The limbic Subcutaneous daratumumab with pomalidomide and dexamethasone (D-Pd) is an effective and...
Phase III Trial Supports Efficacy of Subcutaneous Daratumumab in Relapsed/Refractory Myeloma
This article was originally published on Ash Clinical News Patients with relapsed/refractory multiple myeloma (MM) who were treated with a...
Year in Review: Multiple Myeloma
This article was originally posted on MEDpage Today Despite some concern over a novel ocular toxicity, the FDA granted accelerated...